AtriCure, Inc. (NASDAQ:ATRC) Stock Position Decreased by Great Lakes Advisors LLC

Great Lakes Advisors LLC lowered its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 9.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,742 shares of the medical device company’s stock after selling 7,652 shares during the period. Great Lakes Advisors LLC owned about 0.16% of AtriCure worth $3,689,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in AtriCure by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 4,259,364 shares of the medical device company’s stock worth $279,713,000 after buying an additional 25,066 shares during the last quarter. BlackRock Inc. boosted its position in shares of AtriCure by 3.2% during the first quarter. BlackRock Inc. now owns 3,856,291 shares of the medical device company’s stock worth $159,843,000 after buying an additional 120,525 shares during the period. Invesco Ltd. increased its position in AtriCure by 17.5% in the 1st quarter. Invesco Ltd. now owns 2,865,409 shares of the medical device company’s stock valued at $188,171,000 after acquiring an additional 427,792 shares during the period. First Light Asset Management LLC increased its position in AtriCure by 0.5% in the 1st quarter. First Light Asset Management LLC now owns 1,459,057 shares of the medical device company’s stock valued at $60,478,000 after acquiring an additional 6,543 shares during the period. Finally, Macquarie Group Ltd. boosted its position in AtriCure by 2.4% during the 1st quarter. Macquarie Group Ltd. now owns 1,409,302 shares of the medical device company’s stock worth $58,416,000 after acquiring an additional 33,348 shares during the period. 94.30% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AtriCure

In other news, insider Karl S. Dahlquist sold 1,248 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $34.43, for a total transaction of $42,968.64. Following the transaction, the insider now owns 30,789 shares of the company’s stock, valued at approximately $1,060,065.27. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. BTIG Research increased their target price on shares of AtriCure from $56.00 to $68.00 in a research report on Wednesday, July 26th. JMP Securities assumed coverage on AtriCure in a report on Monday, October 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. JPMorgan Chase & Co. dropped their price target on shares of AtriCure from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Finally, Piper Sandler raised their price objective on shares of AtriCure from $55.00 to $65.00 in a research report on Wednesday, July 26th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.13.

AtriCure Stock Performance

Shares of ATRC opened at $41.94 on Tuesday. AtriCure, Inc. has a one year low of $32.90 and a one year high of $59.61. The company has a 50-day moving average of $39.24 and a two-hundred day moving average of $45.76. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.06 and a quick ratio of 2.31. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -77.67 and a beta of 1.39.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $98.29 million during the quarter, compared to analyst estimates of $96.65 million. AtriCure had a negative return on equity of 6.37% and a negative net margin of 6.52%. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period last year, the company posted ($0.27) EPS. On average, equities research analysts expect that AtriCure, Inc. will post -0.76 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.